ArticleCell metabolism2008
The hepcidin-binding site on ferroportin is evolutionarily conserved.
Article in Cell metabolism, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 56 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 1 synthesis or guideline pooled it, 127 citations in OpenAlex.
- Ferroportin disease: a systematic meta-analysis of clinical and molecular findings.Journal of hepatology · 2010Pooled it
- Article
- A hepatic antimicrobial peptide, hepcidin from Indian major carp, Catla catla: molecular identification and functional characterization.Journal, genetic engineering & biotechnology · 2022Article
- Identification of Antibacterial Activity ofFrontiers in microbiology · 2022Article
- Reduced iron export associated with hepcidin resistance can explain the iron overload spectrum in ferroportin disease.Liver international : official journal of the International Association for the Study of the Liver · 2020Article
- Iron and Alzheimer's Disease: From Pathogenesis to Therapeutic Implications.Frontiers in neuroscience · 2018Review
- Identification of Antibody and Small Molecule Antagonists of Ferroportin-Hepcidin Interaction.Frontiers in pharmacology · 2017Article
- Prophylactic Iron Supplementation in Pregnancy: A Controversial Issue.Biochemistry insights · 2017Review
- The three isoforms of hepcidin in human serum and their processing determined by liquid chromatography-tandem mass spectrometry (LC-tandem MS).International journal of hematology · 2016Article
- Ironing out Ferroportin.Cell metabolism · 2015Review
- Insights into the antimicrobial properties of hepcidins: advantages and drawbacks as potential therapeutic agents.Molecules (Basel, Switzerland) · 2015Review
- Neuroprotective effect of the active components of three Chinese herbs on brain iron load in a mouse model of Alzheimer's disease.Experimental and therapeutic medicine · 2015Article
- Iron-refractory iron deficiency anemia.Turkish journal of haematology : official journal of Turkish Society of Haematology · 2015Article
- Low intracellular iron increases the stability of matriptase-2.The Journal of biological chemistry · 2015Article
- Iron transport across the blood-brain barrier: development, neurovascular regulation and cerebral amyloid angiopathy.Cellular and molecular life sciences : CMLS · 2015Review
- A novel model for brain iron uptake: introducing the concept of regulation.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2015Article
- Prolactin (PRL)-stimulated ubiquitination of ZnT2 mediates a transient increase in zinc secretion followed by ZnT2 degradation in mammary epithelial cells.The Journal of biological chemistry · 2014Article
- Nanopore film based enrichment and quantification of low abundance hepcidin from human bodily fluids.Nanomedicine : nanotechnology, biology, and medicine · 2014Article
- Ceruloplasmin-ferroportin system of iron traffic in vertebrates.World journal of biological chemistry · 2014Review
- Hepcidin in neoplastic disease.Journal of medicine and life · 2013Review
Corrections and comments
- Retraction · 2014-06-03Error in Data · Error in Image · Investigation by Company/Institution · · Ivana De Domeinco aka Ivana Frech has ORI Finding of misconduct: see https://ori.hhs.gov/content/case-summary-de-domenico-ivana
- Commented on by
- Retracted
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
Abstract
Mammalian iron homeostasis is regulated by the interaction of the liver-produced peptide hepcidin and its receptor, the iron transporter ferroportin. Hepcidin binds to ferroportin resulting in degradation of ferroportin and decreased cellular iron export. We identify the hepcidin-binding domain (HBD) on ferroportin and show that a synthetic 19 amino acid peptide corresponding to the HBD recapitulates the characteristics and specificity of hepcidin binding to cell-surface ferroportin. The binding of mammalian hepcidin to ferroportin or the HBD shows an unusual temperature dependency with an increased rate of dissociation at temperatures below 15 degrees C. The increased rate of dissociation is due to temperature- dependent changes in hepcidin structure. In contrast, hepcidin from poikilothermic vertebrates, such as fish or frogs, binds the HBD in a temperature-independent fashion. The affinity of hepcidin for the HBD permits a rapid, sensitive assay of hepcidin from all species and yields insights into the evolution of hepcidin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.